Emerging data suggest this peptide, a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to provide a notable step forward for weight loss . Initial clinical trials have shown substantial losses in visceral fat , possibly exceeding other body compositio